NCT04819373View on ClinicalTrials.gov

BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

PHASE2CompletedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

April 1, 2023

Study Completion Date

May 1, 2023

Conditions

Tumor, Solid

Interventions

DRUG

BDB001

BDB001 is an immunotherapy agent.

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Eikon Therapeutics

All Listed Sponsors

lead

Eikon Therapeutics

INDUSTRY

NCT04819373 - BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Biotech Hunter | Biotech Hunter